Status:

RECRUITING

Oral Anti Diabetic Agents in the Hospital

Lead Sponsor:

Emory University

Collaborating Sponsors:

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Conditions:

Diabetes Mellitus

Eligibility:

All Genders

18-80 years

Phase:

PHASE4

Brief Summary

This randomized controlled clinical trial will assess whether continuation of home oral antidiabetic agents during hospitalization can be used as a safe and effective alternative to insulin therapy in...

Detailed Description

Hyperglycemia in the hospital is common and has been associated with increased hospital complications, length of stay, and mortality. Improving glycemic control has been shown to improve length of sta...

Eligibility Criteria

Inclusion

  • Males or females, age 18-80 years admitted to a general medicine and surgery services
  • Known history of T2D receiving OADs either as monotherapy or in combination therapy
  • Admission BG \< 250 mg/dl or randomization BG \<250 mg/dl and not receiving basal insulin
  • Patients receiving OADs in combination with GLP-1 receptor agonists (GLP-1RA) who have HbA1c \<7.5% within the past three months
  • HbA1c \<10%

Exclusion

  • No known history of diabetes
  • Laboratory evidence of diabetic ketoacidosis
  • Subjects with a history of type 1 diabetes (suggested by BMI \< 25 requiring insulin therapy or with a history of diabetic ketoacidosis, or ketonuria)
  • Meeting any exclusion criteria based on specific contraindications to their home oral therapy
  • Acute critical illness or cardiac surgery expected to require admission to a critical care unit
  • Gastrointestinal obstruction, adynamic ileus, or expected to require gastrointestinal suction
  • Medical or surgical patients expected to be kept NPO for \>24-48 hours after admission or after completion of surgical procedure
  • Impaired renal function (eGFR \<30 ml/min)
  • Current treatment with oral or injectable corticosteroid
  • Mental condition rendering the subject unable to understand the nature and scope of the study
  • Female subjects who are pregnant or breastfeeding at time of enrollment in the study
  • New or recent onset (within two weeks) of coronavirus disease 2019 (COVID-19) infection at the time of admission

Key Trial Info

Start Date :

August 7 2020

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

May 1 2026

Estimated Enrollment :

260 Patients enrolled

Trial Details

Trial ID

NCT04416269

Start Date

August 7 2020

End Date

May 1 2026

Last Update

August 11 2025

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

Emory University Hospital Midtown

Atlanta, Georgia, United States, 30322

2

Emory University Hospital

Atlanta, Georgia, United States, 30322

3

Grady Memorial Hospital

Atlanta, Georgia, United States, 30322